Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nepafenac for prevention of cystoid macular edema after cataract surgery in latanoprost users
ISRCTN38025852Phase 3Completed
- Sponsor
- Chulalongkorn University
- Start
- Jan 2011
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in cystoid macular edema (CME) comparing Continue latanoprost, Continue latanoprost plus nepafenac and Discontinue latanoprost with placebo (3 arms). Primary endpoint: Incidence of postoperative cystoid macular edema. Started Jan 2011; status: completed.
02
Drugs
nepafenaclatanoprost
03
Conditions
cystoid macular edema (CME)
Beyond the preview
Go deeper on ISRCTN38025852.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN38025852.